Top Institutional Investors

Cormorant Asset Management, LP — 13F Holdings & Portfolio

CIK 1583977 · latest 13F-HR filed 2026-08-14

Backtest portfolio

Cormorant Asset Management, LP manages $1.95B in 13F-reported U.S. long-equity assets across 50 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PRAX (10.98%), BBOT (6.98%), PBLS (6.47%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 13 new positions and exited 9; 11 existing positions rose in reported value and 23 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$1.95B

Long-equity book

Holdings
50

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+13 / −9 / ↑11 / ↓23

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
PRAX11.0% · -28%BBOT7.0% · 0%PBLS6.5% · newRAPP5.7% · -10%ERAS5.6% · +3%EWTX5.2% · -23%EYPT5.1% · -15%ALMS4.7% · -17%ABVX4.6% · -11%DNTH3.7% · -21%DRUG3.2% · -15%MLTX3.2% · -28%BIOA3.0% · -17%ORKA2.6% · 0%ANL2.3% · +37%BBIO2.1% · -35%TNGX2.1% · -9%BHVN2.0% · +48%AGMB1.6% · 0%MBX1.6% · -51%CLYM1.4% · newOLMA1.4% · -45%DMRA1.3% · -34%PHVS1.3% · -25%CRBP1.1% · 0%SYRE1.0% · newDFTX1.0% · newNAMS0.9% · -47%ROIV0.9% · -37%CABA0.8% · -9%HLXC0.7% · 0%ASND0.7% · -47%KLRA0.6% · newINSM0.4% · -60%FTH0.4% · newELVN0.4% · newTARS0.3% · -56%IBIO0.3% · newCRNX0.2% · -50%ARQT0.2% · -61%ARWR0.2% · -50%GPCR0.2% · -57%RACC0.2% · newCOGT0.2% · -50%ALT0.2% · newAMLX0.2% · -43%ODTX0.2% · newPCVX0.1% · -50%BOLD0.1% · newQNCX0.0% · new

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 59.2%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated May 27, 2026.

Assets Under Management
$3.84B
Discretionary
$3.84B
Employees
12
Accounts
16
Address
200 CLARENDON STREET
50TH FLOOR
BOSTON, MA 02116
Phone
(857) 702-0370
Website
Name Title / Status Ownership Type
CHEN, BIHUA ControlMANAGING MEMBER & CHIEF EXECUTIVE OFFICER
since Mar 2013
75% or moreIndividual
CORMORANT ASSET MANAGEMENT GP, LLC ControlGENERAL PARTNER
since Mar 2018
Less than 5%Domestic Entity
OBRADOVIC, NEBOJSA ControlCHIEF COMPLIANCE OFFICER & GENERAL COUNSEL
since Jan 2016
Less than 5%Individual
TRIPP, CALEB, JONATHAN ControlCHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER
since Aug 2020
Less than 5%Individual
CHEN, BIHUA Control
Indirect owner via CORMORANT ASSET MANAGEMENT GP, LLC
MANAGING MEMBER
since Mar 2014
75% or moreIndividual
Ownership & leadership changes · 5 filings with changes since Jun 14, 2013

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 30, 2024 filing
  • No longer listedHOYT, WILLIAM, WARREN · CHIEF ADMINISTRATIVE OFFICER & CHIEF OPERATING OFFICER · Less than 5% · control person · listed since Nov 2020
  • ChangedTRIPP, CALEB, JONATHAN · title CHIEF FINANCIAL OFFICER → CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER
Mar 31, 2022 filing
  • No longer listedSCOLLINS, EDWARD, J. · MEMBER, CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER · Less than 5% · control person · listed since Mar 2013
  • AddedHOYT, WILLIAM, WARREN · CHIEF ADMINISTRATIVE OFFICER & CHIEF OPERATING OFFICER · Less than 5% · control person
  • AddedTRIPP, CALEB, JONATHAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ChangedOBRADOVIC, NEBOJSA · title CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER & GENERAL COUNSEL
Mar 29, 2018 filing
  • AddedCHEN, BIHUA · MANAGING MEMBER · 75% or more · indirect via CORMORANT ASSET MANAGEMENT GP, LLC · control person
  • AddedCORMORANT ASSET MANAGEMENT GP, LLC · GENERAL PARTNER · Less than 5% · control person
Jan 12, 2016 filing
  • AddedOBRADOVIC, NEBOJSA · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedSCOLLINS, EDWARD, J. · title MEMBER, CHIEF COMPLIANCE OFFICER, CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER → MEMBER, CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER
Apr 10, 2014 filing
  • ChangedCHEN, BIHUA · title CHIEF EXECUTIVE OFFICER → MANAGING MEMBER & CHIEF EXECUTIVE OFFICER
  • ChangedSCOLLINS, EDWARD, J. · title CHIEF COMPLIANCE OFFICER, CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER → MEMBER, CHIEF COMPLIANCE OFFICER, CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER
Jun 14, 2013 filing (earliest on record)
  • ListedCHEN, BIHUA · CHIEF EXECUTIVE OFFICER · 75% or more · control person
  • ListedSCOLLINS, EDWARD, J. · CHIEF COMPLIANCE OFFICER, CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Cormorant Asset Management, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $214.3M 10.98% 640,000 SH
2 BRIDGEBIO ONCOLOGY THERAPEUT BBOT 107924102 $136.2M 6.98% 17,878,594 SH
3 PARABILIS MEDICINES INC PBLS 698955101 $126.3M 6.47% 4,615,612 SH
4 RAPPORT THERAPEUTICS INC RAPP 75383L102 $110.7M 5.67% 2,657,521 SH
5 ERASCA INC ERAS 29479A108 $109.9M 5.63% 6,000,000 SH
6 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $102.0M 5.23% 2,510,000 SH
7 EYEPOINT INC EYPT 30233G209 $100.1M 5.13% 7,000,000 SH
8 ALUMIS INC ALMS 022307102 $92.5M 4.74% 3,285,596 SH
9 ABIVAX SA ABVX 00370M103 $90.0M 4.61% 675,000 SH
10 DIANTHUS THERAPEUTICS INC DNTH 252828108 $73.1M 3.75% 750,000 SH
11 BRIGHT MINDS BIOSCIENCES INC DRUG 10919W405 $63.2M 3.24% 900,000 SH
12 MOONLAKE IMMUNOTHERAPEUTICS MLTX 61559X104 $62.4M 3.20% 3,205,433 SH
13 BIOAGE LABS INC BIOA 09077V100 $58.6M 3.00% 2,390,605 SH
14 ORUKA THERAPEUTICS INC ORKA 687604108 $50.8M 2.60% 533,340 SH
15 ADLAI NORTYE LTD ANL 00704R109 $45.7M 2.34% 3,978,229 SH
16 BRIDGEBIO PHARMA INC BBIO 10806X102 $41.0M 2.10% 550,000 SH
17 TANGO THERAPEUTICS INC TNGX 87583X109 $40.6M 2.08% 1,300,000 SH
18 BIOHAVEN LTD BHVN G1110E107 $38.8M 1.99% 2,610,000 SH
19 AGOMAB THERAPEUTICS NV AGMB 00860C102 $32.0M 1.64% 2,465,348 SH
20 MBX BIOSCIENCES INC MBX 55287L101 $30.4M 1.56% 550,000 SH
21 CLIMB BIO INC CLYM 28658R106 $27.5M 1.41% 2,106,000 SH
22 OLEMA PHARMACEUTICALS INC OLMA 68062P106 $26.9M 1.38% 2,150,000 SH
23 DAMORA THERAPEUTICS INC DMRA 36322Q206 $26.0M 1.33% 1,000,000 SH
24 PHARVARIS N V PHVS N69605108 $25.9M 1.33% 750,000 SH
25 CORBUS PHARMACEUTICALS HLDGS CRBP 21833P301 $22.0M 1.13% 2,344,971 SH
26 SPYRE THERAPEUTICS INC SYRE 00773J202 $20.0M 1.02% 225,000 SH
27 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $18.8M 0.96% 400,000 SH
28 NEWAMSTERDAM PHARMA COMPANY NAMS N62509109 $16.9M 0.87% 500,000 SH
29 ROIVANT SCIENCES LTD ROIV G76279101 $16.8M 0.86% 475,000 SH
30 CABALETTA BIO INC CABA 12674W109 $15.6M 0.80% 5,000,000 SH
31 HELIX ACQUISITION CORP III HLXC G4444S107 $13.8M 0.71% 1,297,500 SH
32 ASCENDIS PHARMA A/S ASND K08588103 $13.3M 0.68% 50,000 SH
33 KAILERA THERAPEUTICS INC KLRA 482931102 $12.1M 0.62% 550,000 SH
34 INSMED INC INSM 457669307 $8.0M 0.41% 75,000 SH
35 FAETH THERAPEUTICS INC FTH 81728A207 $7.7M 0.39% 1,028,242 SH
36 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $7.6M 0.39% 150,000 SH
37 TARSUS PHARMACEUTICALS INC TARS 87650L103 $6.3M 0.32% 100,000 SH
38 IBIO INC IBIO 451033708 $6.2M 0.32% 3,570,000 SH
39 CRINETICS PHARMACEUTICALS IN CRNX 22663K107 $4.7M 0.24% 125,000 SH
40 ARCUTIS BIOTHERAPEUTICS INC ARQT 03969K108 $4.6M 0.24% 175,000 SH
41 ARROWHEAD PHARMACEUTICALS IN ARWR 04280A100 $4.1M 0.21% 50,000 SH
42 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $4.0M 0.21% 75,000 SH
43 RESEARCH ALLIANCE CORP III RACC G75226103 $4.0M 0.20% 370,000 SH
44 COGENT BIOSCIENCES INC COGT 19240Q201 $3.9M 0.20% 100,000 SH
45 ALTIMMUNE INC ALT 02155H200 $3.8M 0.19% 1,250,000 SH
46 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $3.6M 0.18% 200,000 SH
47 ODYSSEY THERAPEUTICS INC ODTX 67613T104 $3.3M 0.17% 175,000 SH
48 VAXCYTE INC PCVX 92243G108 $2.9M 0.15% 50,000 SH
49 BOUNDLESS BIO INC BOLD 10170A100 $2.5M 0.13% 1,000,000 SH
50 QUINCE THERAPEUTICS INC IRLA 22053A305 $100.0K 0.01% 5,498 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $1.95B 50 0001583977-26-000007
2026-03-31 2026-05-15 $1.99B 47 0001583977-26-000002
2025-12-31 2026-02-17 $2.16B 35 0001583977-26-000001
2025-09-30 2025-11-14 $1.45B 36 0001583977-25-000011
Filer Information
Address
200 CLARENDON STREET
50TH FLOOR
BOSTON, MA 02116
Phone
(857) 702-0388
Filing Manager
Cormorant Asset Management, LP
BOSTON, MA
Signatory
Neb Obradovic
CCO